Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Preferred Stock Liabilities: 2012-2025

Historic Preferred Stock Liabilities for Northwest Biotherapeutics (NWBO) over the last 4 years, with Sep 2025 value amounting to $13.4 million.

  • Northwest Biotherapeutics' Preferred Stock Liabilities fell 15.60% to $13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.4 million, marking a year-over-year decrease of 15.60%. This contributed to the annual value of $15.5 million for FY2024, which is 17.15% down from last year.
  • Per Northwest Biotherapeutics' latest filing, its Preferred Stock Liabilities stood at $13.4 million for Q3 2025, which was down 2.57% from $13.8 million recorded in Q2 2025.
  • Northwest Biotherapeutics' Preferred Stock Liabilities' 5-year high stood at $27.7 million during Q3 2023, with a 5-year trough of $13.4 million in Q3 2025.
  • Moreover, its 3-year median value for Preferred Stock Liabilities was $18.7 million (2023), whereas its average is $18.8 million.
  • Its Preferred Stock Liabilities has fluctuated over the past 5 years, first soared by 101.27% in 2023, then slumped by 42.61% in 2024.
  • Over the past 4 years, Northwest Biotherapeutics' Preferred Stock Liabilities (Quarterly) stood at $23.1 million in 2022, then dropped by 18.83% to $18.7 million in 2023, then fell by 17.15% to $15.5 million in 2024, then fell by 15.60% to $13.4 million in 2025.
  • Its Preferred Stock Liabilities stands at $13.4 million for Q3 2025, versus $13.8 million for Q2 2025 and $14.6 million for Q1 2025.